Cargando…

BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study

To combat the COVID-19 pandemic, a mass vaccination campaign was initiated in Italy on 27 December 2020. The vaccine available to immunize Italian healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine (Comirnaty). This study evaluated the effectiveness of the vaccine against documented SA...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianchi, Francesco Paolo, Tafuri, Silvio, Migliore, Giovanni, Vimercati, Luigi, Martinelli, Andrea, Lobifaro, Annamaria, Diella, Giusy, Stefanizzi, Pasquale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538139/
https://www.ncbi.nlm.nih.gov/pubmed/34696252
http://dx.doi.org/10.3390/vaccines9101143
_version_ 1784588433691246592
author Bianchi, Francesco Paolo
Tafuri, Silvio
Migliore, Giovanni
Vimercati, Luigi
Martinelli, Andrea
Lobifaro, Annamaria
Diella, Giusy
Stefanizzi, Pasquale
author_facet Bianchi, Francesco Paolo
Tafuri, Silvio
Migliore, Giovanni
Vimercati, Luigi
Martinelli, Andrea
Lobifaro, Annamaria
Diella, Giusy
Stefanizzi, Pasquale
author_sort Bianchi, Francesco Paolo
collection PubMed
description To combat the COVID-19 pandemic, a mass vaccination campaign was initiated in Italy on 27 December 2020. The vaccine available to immunize Italian healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine (Comirnaty). This study evaluated the effectiveness of the vaccine against documented SARS-CoV-2 infection and symptomatic diseases in the medium- to long-term. HCWs at Bari Policlinico University-Hospital (Italy) who completed the vaccination schedule were matched with HCWs who had refused vaccination; the two groups were followed-up for 5 months (January–May 2021). Vaccine effectiveness (VE) against infection was 97.7% (95.4–99.0%) at 14–34 days after the first dose, and 94.8% (87.0–97.8%), 83.0% (65.0–92.0%), and 81.0% (42.0–94.0%) at 14–41, 42–69, and >69 days, respectively, after the second dose. The estimated VE for documented symptomatic disease was 99.2% (96.4–99.8%) at 14–34 days after the first dose and 97.2% (90.3–99.2%), 85.0% (63.0–94.2%), and 88.0% (42.0–97.6%) at 14–41, 42–69, and >69 days, respectively, after the second dose. Efforts to increase vaccination rates should be strengthened, including mandatory vaccination for HCWs and greater incentives to increase vaccine acceptance by the general population.
format Online
Article
Text
id pubmed-8538139
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85381392021-10-24 BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study Bianchi, Francesco Paolo Tafuri, Silvio Migliore, Giovanni Vimercati, Luigi Martinelli, Andrea Lobifaro, Annamaria Diella, Giusy Stefanizzi, Pasquale Vaccines (Basel) Article To combat the COVID-19 pandemic, a mass vaccination campaign was initiated in Italy on 27 December 2020. The vaccine available to immunize Italian healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine (Comirnaty). This study evaluated the effectiveness of the vaccine against documented SARS-CoV-2 infection and symptomatic diseases in the medium- to long-term. HCWs at Bari Policlinico University-Hospital (Italy) who completed the vaccination schedule were matched with HCWs who had refused vaccination; the two groups were followed-up for 5 months (January–May 2021). Vaccine effectiveness (VE) against infection was 97.7% (95.4–99.0%) at 14–34 days after the first dose, and 94.8% (87.0–97.8%), 83.0% (65.0–92.0%), and 81.0% (42.0–94.0%) at 14–41, 42–69, and >69 days, respectively, after the second dose. The estimated VE for documented symptomatic disease was 99.2% (96.4–99.8%) at 14–34 days after the first dose and 97.2% (90.3–99.2%), 85.0% (63.0–94.2%), and 88.0% (42.0–97.6%) at 14–41, 42–69, and >69 days, respectively, after the second dose. Efforts to increase vaccination rates should be strengthened, including mandatory vaccination for HCWs and greater incentives to increase vaccine acceptance by the general population. MDPI 2021-10-07 /pmc/articles/PMC8538139/ /pubmed/34696252 http://dx.doi.org/10.3390/vaccines9101143 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bianchi, Francesco Paolo
Tafuri, Silvio
Migliore, Giovanni
Vimercati, Luigi
Martinelli, Andrea
Lobifaro, Annamaria
Diella, Giusy
Stefanizzi, Pasquale
BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study
title BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study
title_full BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study
title_fullStr BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study
title_full_unstemmed BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study
title_short BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study
title_sort bnt162b2 mrna covid-19 vaccine effectiveness in the prevention of sars-cov-2 infection and symptomatic disease in five-month follow-up: a retrospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538139/
https://www.ncbi.nlm.nih.gov/pubmed/34696252
http://dx.doi.org/10.3390/vaccines9101143
work_keys_str_mv AT bianchifrancescopaolo bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy
AT tafurisilvio bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy
AT miglioregiovanni bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy
AT vimercatiluigi bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy
AT martinelliandrea bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy
AT lobifaroannamaria bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy
AT diellagiusy bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy
AT stefanizzipasquale bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy
AT bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy